The effect of adjuvant chemotherapy on symptom burden and quality of life over time; a preliminary prospective observational study using individual data of patients aged ≥ 70 with early stage invasive breast cancer

e19519 Background: Breast cancer therapy related neurocognitive dysfunction, such as memory impairment and “chemo-brain”, has been reported by many women during and after receiving adjuvant chemotherapy. Studies evaluating this effect have had mixed results regarding its validity. No study has evaluated a specific regimen and none have examined dose dense therapy. We have serially evaluated the cognitive and quality of life changes in patients receiving dose dense adjuvant adriamycin/cyclophosphamide followed by pactitaxel (DD AT-P) chemotherapy. Methods: Patients with early stage breast cancer (Stages I, II) who were treated at a single community hospital cancer center and were given dose dense AC-P adjuvant chemotherapy were asked to participate in this trial. 45 patients were enrolled and 43 were eligible for evaluation with the following instruments: FACT-F, FAS test, MMSE, MNA and BDI. Tests were administered at the start of chemotherapy, at the completion of chemotherapy, at 6 months and 12 months after completing chemotherapy. The tests were administered by oncology nurses. Scores were evaluated using repeated measures analysis of variance testing whether or not the change from baseline test scores had a trend over time. Results: 43 patients were evaluated. Age range was 34-72 years with a median age of 52. 34 patients completed 4 evaluations, 6 completed 3 evaluations, 3 completed 2 evaluations. The only measures demonstrating significant trends were the FAS test (p=0.022) and the Functional Well-Being (p=0.002) and Physical Well-Being (p<0.0001) portions of the FACT-F. The changes over time for these measures all indicated improved performance over baseline at the completion of the trial. The remainder of the tests showed no significant change over time. Conclusions: Dose dense adjuvant chemotherapy with AC-P for breast cancer does not result in decreased cognitive or quality of life measures over time. Patients can be reassured that this specific program of therapy will not lead to long term decreases in mental function and quality of life.

Download Full-text

Health-related quality of life of early-stage breast cancer patients after different radiotherapy regimens

Breast Cancer Research and Treatment ◽

10.1007/s10549-021-06314-4 ◽

2021 ◽

Author(s):

Daphne H. M. Jacobs ◽

Ramona K. Charaghvandi ◽

Nanda Horeweg ◽

John H. Maduro ◽

Gabrielle Speijer ◽

...

Keyword(s):

Breast Cancer ◽

Quality Of Life ◽

Early Stage ◽

Early Stage Breast Cancer ◽

Breast Irradiation ◽

Health Related Quality ◽

Related Quality ◽

Health Related ◽

Over Time

Abstract Purpose To evaluate and compare health-related quality of life (HRQL) of women with early-stage breast cancer (BC) treated with different radiotherapy (RT) regimens. Methods Data were collected from five prospective cohorts of BC patients treated with breast-conserving surgery and different RT regimens: intraoperative RT (IORT, 1 × 23.3 Gy; n = 267), external beam accelerated partial breast irradiation (EB-APBI, 10 × 3.85 Gy; n = 206), hypofractionated whole breast irradiation(hypo-WBI, 16 × 2.67 Gy; n = 375), hypo-WBI + boost(hypo-WBI-B, 21–26 × 2.67 Gy; n = 189), and simultaneous WBI + boost(WBI-B, 28 × 2.3 Gy; n = 475). Women ≥ 60 years with invasive/in situ carcinoma ≤ 30 mm, cN0 and pN0-1a were included. Validated EORTC QLQ-C30/BR23 questionnaires were used to asses HRQL. Multivariable linear regression models adjusted for confounding (age, comorbidity, pT, locoregional treatment, systemic therapy) were used to compare the impact of the RT regimens on HRQL at 12 and 24 months. Differences in HRQL over time (3–24 months) were evaluated using linear mixed models. Results There were no significant differences in HRQL at 12 months between groups except for breast symptoms which were better after IORT and EB-APBI compared to hypo-WBI at 12 months (p < 0.001). Over time, breast symptoms, fatigue, global health status and role functioning were significantly better after IORT and EB-APBI than hypo-WBI. At 24 months, HRQL was comparable in all groups. Conclusion In women with early-stage breast cancer, the radiotherapy regimen did not substantially influence long-term HRQL with the exception of breast symptoms. Breast symptoms are more common after WBI than after IORT or EB-APBI and improve slowly until no significant difference remains at 2 years posttreatment.

Download Full-text

Quality of life and psychological distress during cancer: a prospective observational study involving young breast cancer female patients

BMC Cancer ◽

10.1186/s12885-020-07272-8 ◽

2020 ◽

Vol 20 (1) ◽

Author(s):

Barbara Muzzatti ◽

Francesca Bomben ◽

Cristiana Flaiban ◽

Marika Piccinin ◽

Maria Antonietta Annunziata

Keyword(s):

Breast Cancer ◽

Quality Of Life ◽

Psychological Distress ◽

Observational Study ◽

Prospective Observational Study ◽

Female Patients ◽

Young Breast Cancer

Download Full-text

Variability of Patterns of Fatigue and Quality of Life Over Time Based on Different Breast Cancer Adjuvant Chemotherapy Regimens

Oncology Nursing Forum ◽

10.1188/09.onf.563-570 ◽

2009 ◽

Vol 36 (5) ◽

pp. 563-570 ◽

Cited By ~ 40

Author(s):

Ann M. Berger ◽

Kari Lockhart ◽

Sangeeta Agrawal

Keyword(s):

Breast Cancer ◽

Quality Of Life ◽

Adjuvant Chemotherapy ◽

Over Time

Download Full-text

1555 BEAUTY, a large randomised controlled trial of beauty care for early stage breast cancer patients receiving adjuvant chemotherapy: Impact on body image-related quality of life

European Journal of Cancer ◽

10.1016/s0959-8049(16)30645-1 ◽

2015 ◽

Vol 51 ◽

pp. S222-S223

Author(s):

M. Saghatchian d'Assignies ◽

A. Laplanche ◽

M. Fekih ◽

E. Pezant ◽

N. Bouvet ◽

...

Keyword(s):

Breast Cancer ◽

Quality Of Life ◽

Adjuvant Chemotherapy ◽

Early Stage ◽

Controlled Trial ◽

Breast Cancer Patients ◽

Related Quality ◽

Randomised Controlled ◽

Beauty Care

Download Full-text

A prospective study on behavioral symptoms’ impact to the quality of life in patients with early-stage cancer receiving radiotherapy.

Journal of Clinical Oncology ◽

10.1200/jco.2013.31.26_suppl.46 ◽

2013 ◽

Vol 31 (26_suppl) ◽

pp. 46-46

Author(s):

Canhua Xiao ◽

Jennifer Felger ◽

Donna Mister ◽

Tian Liu ◽

Andrew H. Miller ◽

...

Keyword(s):

Breast Cancer ◽

Quality Of Life ◽

Prospective Study ◽

Cancer Patients ◽

Early Stage ◽

Behavioral Symptoms ◽

Breast Cancer Patients ◽

A Prospective Study ◽

Over Time

46 Background: Fatigue, sleep problems, and depression are the most common behavioral symptoms experienced by breast cancer patients. The purpose of this study was to examine these behavioral symptoms’ impact on quality of life (QOL) for early stage breast cancer patients receiving radiotherapy (RT). Methods: This was a prospective study of 46 patients receiving whole breast RT (50 Gy plus a 10 Gy boost) following lumpectomy. Data were collected at pre-RT, week 6 of RT, and 6-weeks post-RT. QOL was measured by Short Form-36, fatigue by Multidimensional Fatigue Inventory, sleep by Pittsburgh Sleep Quality Index, depression by Inventory for Depressive Symptomatology-Self-Rated, and stress by Perceived Stress Scale. No patients were treated with chemotherapy. Demographic/clinical variables, including age, race, marriage, smoking history, hormone treatment, and cancer stage, were collected at the time of enrollment. Mixed effect modeling was utilized to observe behavioral symptoms’ impact on QOL over time. Results: Fatigue and depression, along with stress, had significant impact on QOL after controlling for body mass index (BMI; the only one significant demographic/clinical variable; see Table). Patients with more fatigue, depression, or stress were more likely to have worse QOL during and post-RT. Patients having a higher BMI at baseline also reported worse QOL over time. Sleep was significantly correlated with QOL in univariate analyses, while this effect disappeared in multivariate models. Conclusions: Behavioral symptoms, in particular fatigue and depression, along with stress, have significant impact on the QOL of early breast cancer patients’ receiving RT. Future research on the underlying biological mechanisms will improve our understanding of these symptoms and their relationships, which will help to find potential targets for multiple related symptoms and, ultimately, improve patients’ QOL. [Table: see text]

Download Full-text